US lawmakers question FDAs drug inspection programme in India and China
By Lalit K Jha
PTI, Jun 25, 2024, 8:47 AM IST
Representative image
Washington: Three top American lawmakers have questioned the foreign drug inspection programme of the Food and Drug Administration in India and China.
In a letter to FDA commissioner Robert Califf, the lawmakers on Monday wrote that the difference in inspection outcomes appears to be just another example of institutional weaknesses and dysfunction in the FDA’s foreign drug inspection programme.
The letter dated June 21 was written by House Energy and Commerce committee chair Cathy McMorris Rodgers, subcommittee on health chair Brett Guthrie, and subcommittee on Oversight and Investigations Chair Morgan Griffith following the analysis of the outcomes of FDA inspections in India and China from January 2014 to April 2024.
“The results of this analysis were surprising, revealing tremendous variation in inspection outcomes. Some FDA inspectors found compliance issues during all or almost all of their inspections. Other inspectors rarely reported finding a single compliance issue. Two inspectors never found a single compliance issue throughout a combined 24 inspections in India,” they wrote.
Another inspector found zero compliance issues in 20 out of 23 inspections (85 percent) in China while finding compliance issues in almost half of domestic inspections during the same period. These are unusual inspection outcomes, the opposite of what would be expected given the widely reported failures in quality control and lack of adherence to current good manufacturing techniques by drug manufacturing facilities in China and India, the lawmakers wrote.
“By contrast, 16 FDA inspectors, with over 325 inspections collectively in India, found compliance issues during every inspection they conducted. As a measure of what a pattern of rigorous inspections should look like, the committee reviewed the inspection outcomes for 3 FDA inspectors with a professional reputation for thoroughness who also had at least 10 inspections in China or India during the studied period,” they wrote.
These expert inspectors reported finding no compliance issues during inspections in China at a rate of only 6.7 to 11.4 percent and at a rate of zero to 9.5 percent in India, they said, adding that such large variations in inspection outcomes are troubling, and they merit further investigation. At a minimum, the committee is concerned that these findings suggest vast differences in the skill, thoroughness, and competence of FDA inspectors.
As such, the lawmakers pressed for more information regarding the agency’s foreign drug inspection programme.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Biden and Trump call each other liar worst president during testy presidential debate
‘Furious’ Rishi Sunak tries to override betting scandal in UK election campaign
Indian-origin woman wrongly jailed in UK during pregnancy rejects apology
Kenya violence: Indian nationals advised to exercise ‘utmost caution’
WikiLeaks’ Assange pleads guilty in deal with US that secures his freedom, ends legal fight
MUST WATCH
Latest Additions
Govt approves 40 pc risk allowance for NDRF rescuers: Amit Shah
Govt approves 40 pc risk allowance for NDRF rescuers: Amit Shah
Kerala: ED attaches land, bank deposits of CPI(M) in money laundering case
BJP will be wiped out from Jharkhand after assembly elections: Hemant Soren
Karnataka police arrest man in Mumbai for duping people over medical seats
Thanks for visiting Udayavani
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.